AstraZeneca to invest $50 billion in the U.S. in 2030 amid Trump tariff threat | AstraZeneca

Astrazeneca announced it would invest $50 billion (£37 billion) in the U.S. by 2030, the latest pledge from pharmaceutical companies as the threat to the industry as Donald Trump’s tariffs pose a threat to the industry as a whole.

The Cambridge-based British drugmaker said its investment will fund new drug manufacturing facilities in Virginia and expand its research and development and cell therapy manufacturing industries in Maryland, Massachusetts, California, Indiana and Texas.

Announcement is Trump threatens to impose up to 200% tariffs on drugs made outside the U.S.. The president said last month that pharmaceutical companies could be offered between 12 and 18 months to bring their manufacturing to the United States.

U.S. Commerce Secretary Howard Lutnick said Trump’s tariffs are focused on ending their dependence on supplying major pharmaceutical products abroad.

“We have decided to bring a lot of drug production to our coasts for Astrazeneca. This historic investment is bringing tens of thousands of jobs to the United States and will ensure that medicines are produced here,” he said.

AstraZeneca CEO Pascal Soriot said the $50 billion investment will support the company’s $8 billion revenue by 2030, when 50% of sales are expected to come from the U.S. The company received $54.1 billion in revenue in 2024.

Faced with potential punitive tariffs, Astrazeneca joined a series of companies to unveil investments in the United States.

Swiss drugmaker Roche Roche announced in April US manufacturing industry $5 billion Over the next five years, it claims to create more than 12,000 jobs. Its rival Novartis said it would spend $23 billion in the U.S., while U.S. pharmaceutical company Johnson & Johnson said in March that it would invest $5.5 billion in manufacturing and research and development.

The Trump administration has conducted an investigation into the pharmaceutical industry, believing that foreign imports are internationally safe and that the “most popular country” pricing is

He said in May that the U.S. would “no longer tolerate profits and prices of big pharmaceutical companies.”

Technology companies have also strengthened their commitment to the United States due to rising political pressures. February, Apple announces $50 billion in the U.S. Over the next four years, a giant factory in Texas is included for AI servers.

AstraZeneca’s multi-billion dollar commitment to the United States follows era That Soriot – one The highest executive in the FTSE 100 – Hope to transfer the company’s stock market listing from London to New York.

Such actions will be handled A major blow to the UK stock marketwhich has suffered a series of departures from companies seeking higher valuations. The pharmaceutical company is one of the largest listed businesses in London with a market value of £158.7 billion.